Short answer
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an 8-K current report with the SEC on October 29, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q3 FY2026 financial results for the quarter ended September 30, 2026 announced.
SUPERNUS PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 FY2026 financial results for the quarter ended September 30, 2026 announced
- Investor focus: detailed revenue, earnings and guidance metrics in Exhibit 99.1
- Management conference call scheduled October 29, 2026 at 4:30 p.m. Eastern Time
- Archived webcast available on Supernus’ website for 60 days
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 revenue $226.8M, up 18%, with growth products revenue $192.2M, up 29%
- Qelbree sales $90.8M, up 12%, while ZURZUVAE collaboration revenue reached $41.7M, up 107%
- ONAPGO sales $17.1M, up 151%, supported by seven-year orphan exclusivity and a second-supplier sNDA
- GAAP operating earnings $21.2M versus a $60.2M loss, while net earnings reached $20.9M, or $0.35 diluted EPS
- Indivior merger expected November 2, 2026, with $125M annual synergies and Nasdaq trading under SUPN beginning November 3
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SUPERNUS PHARMACEUTICALS, INC. 8-K filings
Get the next SUPN 8-K as it lands
Follow SUPN for push alerts, or ask the research agent what this filing means.